Medical News
Viral Reservoir in Early-Treated HIV-Infected Children and...
Nutr Metab
Lower viral reservoir was associated with starting ART at <1 week. Negative serostatus and qualitative DNA were...
22 Feb 2021
Weight Gain Following ART Initiation in ART-Naïve People Liv...
JAIDS
There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we...
12 Feb 2021
Differences in Types of Myocardial Infarctions Among People...
JAIDS
Rates of T2MIs were higher than T1MIs until age 40 years among PLWH, differing from the general population, but...
09 Feb 2021
Immunodeficiency and Cancer in 3.5 Million People Living wit...
Clin Infect Dis
Lower CD4 cell counts were associated with an increased risk of developing various infection-related cancers among...
03 Feb 2021
eCMEs
Key Trials
Efficacy of Reduced Doses of both TDF and EFV for the Treatment of HIV-1 Infection
This study is the first randomized, controlled trial in an antiretroviral-naive population that evaluated the efficacy of reduced doses of both...
144-week Efficacy and Safety of Fixed-dose Combination Bictegravir, Emtricitabine, and Tenofovir alafenamide versus Dolutegravir-containing Regimens for Initial Treatment of HIV-1 Infection
This is a randomised, double-blind, multicentre, phase 3 trial evaluating 144-week efficacy and safety of fixed-dose combination bictegravir,...
Long Acting Injectables (CAB+RPV) for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase III ATLAS and FLAIR Studies
The present study is the pooled analysis of two phase III studies, ATLAS and FLAIR, that compared efficacy and safety of monthly intramuscular (IM)...
ADVANCE Trial: 96-week Efficacy and Safety of DTG Combined with FTC and TAF or TDF versus EFV Combined with FTC and TDF
The ADVANCE trial compared the efficacy and safety of a triple-therapy combination of emtricitabine and dolutegravir plus either of two tenofovir...
Our Publications
Antiretroviral-based Prevention Strategies in HIV
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Antiretroviral Therapy – Current Recommendations
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
Patient Education
Live Healthier, Live Longer
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....
Living with Hope
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...
Slide Library
HIV - HCV Coinfection
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
HIV- Post-exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
Isoniazid Preventive Therapy in HIV Infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....
Infographics
Poll
Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
Efavirenz 400
Dolutegravir
Total votes: 6